UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 883

Sortiert nach

Small-cell lung cancer: what we know, what we need to know and the path forward

Nature reviews. Cancer, 2017-12, Vol.17 (12), p.725

2017

Link zum Volltext

Verfügbarkeit prüfen

New and emerging targeted treatments in advanced non-small-cell lung cancer

The Lancet (British edition), 2016-09, Vol.388 (10048), p.1012-1024

2016

Link zum Volltext

Verfügbarkeit prüfen

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3334-3347

2018

Link zum Volltext

Verfügbarkeit prüfen

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1666-1671

2019

Link zum Volltext

Verfügbarkeit prüfen

2020 Innovation‐Based Optimism for Lung Cancer Outcomes

The oncologist (Dayton, Ohio), 2021-03, Vol.26 (3), p.e454-e472

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

CA: a cancer journal for clinicians, 2023-11, Vol.73 (6), p.620-652

2023

Link zum Volltext

Verfügbarkeit prüfen

Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016

Journal of clinical oncology, 2017-01, Vol.35 (2), p.243-252

Bunn, Jr, Paul A

2017

Link zum Volltext

Verfügbarkeit prüfen

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1807-1814

2012

Link zum Volltext

Verfügbarkeit prüfen

Worldwide overview of the current status of lung cancer diagnosis and treatment

Archives of pathology & laboratory medicine (1976), 2012-12, Vol.136 (12), p.1478-1481

Bunn, Jr, Paul A

2012

Link zum Volltext

Verfügbarkeit prüfen

Classification of lung cancer histology by gold nanoparticle sensors

Nanomedicine, 2012-07, Vol.8 (5), p.580-589

2012

Link zum Volltext

Verfügbarkeit prüfen

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

PloS one, 2013-12, Vol.8 (12), p.e82236

2013

Link zum Volltext

Verfügbarkeit prüfen

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Cancer, 2012-09, Vol.118 (18), p.4502-4511

2012

Link zum Volltext

Verfügbarkeit prüfen

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Cancer, 2017-11, Vol.123 (21), p.4099-4105

2017

Link zum Volltext

Verfügbarkeit prüfen

Recent Clinical Advances in Lung Cancer Management

Journal of clinical oncology, 2014-04, Vol.32 (10), p.973-982

2014

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Journal of clinical oncology, 2003-10, Vol.21 (20), p.3798-3807

2003

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2248-2255

2012

Link zum Volltext

Verfügbarkeit prüfen

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

The Journal of clinical investigation, 2023-01, Vol.133 (2), p.1-9

2023

Link zum Volltext

Verfügbarkeit prüfen

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next‐Generation Sequencing for Detection of EML4‐ALK Rearrangement in Lung Cancer

The oncologist (Dayton, Ohio), 2015-03, Vol.20 (3), p.316-322

2015

Link zum Volltext

Verfügbarkeit prüfen

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.946-963

2016

Link zum Volltext

Verfügbarkeit prüfen

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Cancer, 2016-03, Vol.122 (5), p.766-772

2016

Link zum Volltext

Verfügbarkeit prüfen

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Molecular cancer therapeutics, 2007-06, Vol.6 (6), p.1683-1691

2007

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

JNCI : Journal of the National Cancer Institute, 2005-05, Vol.97 (9), p.643-655

2005

Link zum Volltext

Verfügbarkeit prüfen

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2015-05, Vol.10 (5), p.768-777

2015

Link zum Volltext

Verfügbarkeit prüfen

New Developments in Neoadjuvant Therapy for Lung Cancer

Oncology (Williston Park, N.Y.), 2019-03, Vol.33 (3), p.101-109

2019

Link zum Volltext

Verfügbarkeit prüfen

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.944-950

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 883

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(812)
Mit Volltextzugriff
(788)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(492)
Life Sciences & Biomedicine
(444)
Humans
(433)
Oncology
(272)
Biological And Medical Sciences
(192)
Female
(184)
Medical Sciences
(182)
Male
(177)
Lung Neoplasms - Drug Therapy
(144)
Middle Aged
(137)
Aged
(123)
Lung Neoplasms - Pathology
(110)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(107)
Adult
(106)
Pneumology
(85)
Tumors Of The Respiratory System And Mediastinum
(85)
Pharmacology. Drug Treatments
(81)
Respiratory System
(79)
Antineoplastic Agents
(76)
Lung Cancer
(68)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Small-cell lung cancer: what we know, what we need to know and the path forward

New and emerging targeted treatments in advanced non-small-cell lung cancer

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

2020 Innovation‐Based Optimism for Lung Cancer Outcomes

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Worldwide overview of the current status of lung cancer diagnosis and treatment

Classification of lung cancer histology by gold nanoparticle sensors

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Recent Clinical Advances in Lung Cancer Management

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next‐Generation Sequencing for Detection of EML4‐ALK Rearrangement in Lung Cancer

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

New Developments in Neoadjuvant Therapy for Lung Cancer

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines

Suchergebnisse filtern